PHARVARIS N.V. EO -12
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema… Read more
Market Cap & Net Worth: PHARVARIS N.V. EO -12 (9EN)
PHARVARIS N.V. EO -12 (F:9EN) has a market capitalization of $1.53 Billion (€1.49 Billion) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #8266 globally and #884 in its home market, demonstrating a 3.60% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PHARVARIS N.V. EO -12's stock price €23.00 by its total outstanding shares 64959454 (64.96 Million).
PHARVARIS N.V. EO -12 Market Cap History: 2021 to 2026
PHARVARIS N.V. EO -12's market capitalization history from 2021 to 2026. Data shows growth from $926.84 Million to $1.53 Billion (1.34% CAGR).
PHARVARIS N.V. EO -12 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PHARVARIS N.V. EO -12's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 9EN by Market Capitalization
Companies near PHARVARIS N.V. EO -12 in the global market cap rankings as of March 19, 2026.
Key companies related to PHARVARIS N.V. EO -12 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
PHARVARIS N.V. EO -12 Historical Marketcap From 2021 to 2026
Between 2021 and today, PHARVARIS N.V. EO -12's market cap moved from $926.84 Million to $ 1.53 Billion, with a yearly change of 1.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.53 Billion | +6.48% |
| 2025 | €1.44 Billion | +18.68% |
| 2024 | €1.21 Billion | -27.20% |
| 2023 | €1.67 Billion | +142.72% |
| 2022 | €686.79 Million | -25.90% |
| 2021 | €926.84 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of PHARVARIS N.V. EO -12 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.53 Billion USD |
| MoneyControl | $1.53 Billion USD |
| MarketWatch | $1.53 Billion USD |
| marketcap.company | $1.53 Billion USD |
| Reuters | $1.53 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.